Vitamin K2 MK-7.

The gap this formula speaks to.

Public health figures the engine matched to this formula's ingredients. Reported by their source, cited and dated, never written by the brand.

Population figures from public health data. Context for the category, not a statement about any individual and not a claim about this product.

Every one of these is a fact the engine could ground.

Each line below was derived from this formula's own record at the time of verification. Nothing here was written by the brand, and nothing can be added that the evidence does not carry.

• Studied in people13 human studies on Vitamin K2 (as menaquinone-7) back this formula, each one cited.
• A mechanism that is settledHow Vitamin K2 (as menaquinone-7) works is settled pharmacology.
• Recent work on the recordThe most recent study on this record was published in 2026.
• Serving amount inside the studied rangeEach serving carries 100 mcg of Vitamin K2 (as menaquinone-7), inside the range the published research used.
• A stated daily maintenance amountVitamin K2 (as menaquinone-7) is here at a daily maintenance amount, which is what a daily supplement is for.
• Why this formatIt is a softgel, so the active is already dissolved in oil and the shell keeps it away from air and light.
• The exact form, describedThe form on the label is MK-7, all-trans menaquinone-7. The record says what that form is and what it suits.
• Full label disclosureEvery ingredient on this label carries its own declared amount.
• Where it comes from and how it is madeVitamin K2 (as menaquinone-7) is made by more than one route.
• Positions this formula already qualifies forThis formula already qualifies for positions beyond the one it is sold into, on the evidence it carries.

What the trials show about timing.

Time-to-effect windows the engine read from the trial record. Each is a window a named study measured, cited and dated, never written by the brand.

• Vitamin K2 (as menaquinone-7)about four weeks of daily useBuilds with daily use

  A double-blind randomised dose-finding trial gave 60 postmenopausal women aged 50 to 69 either 0, 50, 100 or 200 micrograms of menaquinone-7 daily for four weeks on a controlled diet. The ratio of carboxylated to undercarboxylated osteocalcin rose dose dependently, with significant differences from the 0 microgram group at 100 and 200 micrograms. A companion 12-week trial in 120 people aged 20 to 69 confirmed the change at 100 micrograms daily. Both studies were run by authors affiliated with the R and D division of J-Oil Mills. An independent 8-week double-blind trial in 55 healthy prepubertal children found the same direction at 45 micrograms daily. What was measured is a blood marker of vitamin K status, not bone density and not a sensation.

  Inaba et al., 2015 (J Nutr Sci Vitaminol (Tokyo))PMID 26875489

  van Summeren et al., 2009 (Br J Nutr)PMID 19450370

  Promising
• Vitamin K2 (as menaquinone-7)three years of daily use, with measurements at one, two and three yearsBuilds with daily use

  A double-blind randomised trial gave 244 healthy postmenopausal women either placebo or 180 micrograms of menaquinone-7 daily for three years, with bone mineral density measured by DXA at baseline and after each year. Menaquinone-7 decreased the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck, but not at the total hip. The effect is a slowed decline rather than a gain, and the trial ran three years rather than weeks.

  Knapen et al., 2013 (Osteoporos Int)PMID 23525894

  Promising

Windows measured in the cited trials. Context for how the active behaves over time, not a statement about any individual and not a claim about this product.

How each ingredient usually behaves over time.

One ingredient, from its own page.

• Vitamin K2 (as menaquinone-7)Days, not hours

  Days for absorption, weeks for the marker. Undercarboxylated osteocalcin falls across roughly four to twelve weeks of daily intake, and that is a status marker rather than an outcome.

  Its own page, the plain answer on timing ↗

How each ingredient usually behaves over time, from its own page on IngredientMD. General timing for the ingredient, not a measurement of this product.

The same ingredient, carried differently.

What each form is, and where it fits in a formula. Measured findings carry the study that reported them.

• Menaquinone-7 (MK-7)

  The long-side-chain menaquinone, usually made by bacterial fermentation of the kind that gives natto its K2. The seven-unit tail keeps it circulating far longer than the short-chain MK-4, which is why microgram doses are the convention.

  Fits

  Formulas that want a once-daily microgram-level K2 with a fermentation-sourced supply chain.

  Trade-off

  Trial outcomes beyond raising K2 status take months to years to read out, and the muscle-recovery use tested recently showed nothing over placebo.

  In a 12-week double-blind randomised controlled trial, 71 healthy young and older adults took menaquinone-7 at 240 micrograms daily or placebo. Circulating MK-7 rose with supplementation, while recovery from a bout of muscle-damaging resistance exercise did not differ from placebo on strength, function, soreness or inflammatory markers.

  Lithgow et al., 2026 (Medicine and Science in Sports and Exercise)PMID 41843412

Descriptions of the form itself, read from the cited studies. Not a comparison between products and not a statement about any individual.

Softgel

It is a softgel, so the active is already dissolved in oil and the shell keeps it away from air and light.

Studied alongside this brand's other formulas

Where two of this brand's products carry actives the literature has read together, the pairing and its basis are below. The evidence word is the corpus row's own confidence, never a score.